Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Oxoisovalerate SCHEMBL1462512 | 0.79 | TP53 (0.41) | TSHRTP53SLC7A5FFAR3LCK | |
| SCHEMBL10308365 | 0.79 | TSHR (0.42) | TSHRTP53ALDH1A1LMNATDP1 | |
| 2-Oxoisovalerate SCHEMBL30552298 | 0.79 | — | — | |
| SCHEMBL6992690 | 0.79 | — | — | |
| SCHEMBL107888 | 0.79 | — | — | |
| SCHEMBL10308369 | 0.79 | TSHR (0.42) | TSHRTP53ALDH1A1LMNATDP1 | |
| 2-Oxoisovalerate SCHEMBL42329 | 0.79 | — | — | |
| SCHEMBL2214959 | 0.76 | — | — | |
| 2-Oxoisovalerate SCHEMBL6846904 | 0.76 | — | — | |
| SCHEMBL642131 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 427 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463374-A2 | Isolated alcohol dehydrogenase enzymes and uses thereof | Bio Architecture Lab, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| EP-2195440-A2 | BIOFUEL PRODUCTION | Bio Architecture Lab, Inc. (US) | 2010-06-16 | — | — | EP | claimed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | claimed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | claimed |
| WO-2009046375-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| WO-2009046370-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| US-7285688-B2 | Proton type β zeolite, preparation method thereof and process for preparing phenol compound using the same | UBE INDUSTRIES, LTD. (JP) | 2007-10-23 | — | — | US | claimed |
| US-5618982-A | SIMPLE INDUSTRIAL PROCESS OF CATALYZING IN PRESENCE OF METALLIC PHOSPHATES | RHONE-POULENC CHIMIE (FR) | 1997-04-08 | — | — | US | claimed |
| US-4084970-A | Organic volume phase holographic recording media using sucrose benzoate | RCA CORPORATION (US) | 1978-04-18 | — | — | US | claimed |
| EP-3230463-B2 | RAPID PRETREATMENT | APALTA PATENTS OUE (EE) | 2025-07-16 | — | — | EP | disclosed |
| US-20240425893-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2024-12-26 | — | — | US | disclosed |
| WO-2024234728-A1 | 6'-CYANO-MODIFIED LOCKED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID POLYMER | 中国人民解放军军事科学院军事医学研究院 | 2024-11-21 | — | — | WO | disclosed |
| US-12054761-B2 | Rapid pretreatment | Apalta Patents OÜ (EE) | 2024-08-06 | — | — | US | disclosed |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-4608423-A | Linear addition polyester copolymers | SCM CORPORATION (US) | 1986-08-26 | — | — | US | disclosed |
| US-4547323-A | Synthesis of 2,2-dimethyl-4-methyleneglutaric acid and derivatives | SCM CORPORATION (US) | 1985-10-15 | — | — | US | disclosed |
| US-4526945-A | Copolymerizing methacrylic monomer or methacrylic and ethylenic monomers in the presence of free radical catalyst and cobalt glyoxime catalyst | SCM CORPORATION (US) | 1985-07-02 | — | — | US | disclosed |
| US-4084970-A | Organic volume phase holographic recording media using sucrose benzoate | RCA CORPORATION (US) | 1978-04-18 | — | — | US | disclosed |
| US-3956317-A | HIGH HEAT DISTORTION POINT | CIBA-GEIGY AG (CH) | 1976-05-11 | — | — | US | disclosed |
| US-3951663-A | Organic volume phase holographic recording media comprising an α di-ketone | RCA CORPORATION (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | TSHR 3236/4885TP53 559/4885ALDH1A1 868/4885 |
| US-20090139134-A1 | BIOFUEL PRODUCTION | MGAM, DCXR, MANBA | TSHR 3426/4885TP53 3946/4885ALDH1A1 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.